These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 36983017)

  • 1. mRNA Vaccines against SARS-CoV-2: Advantages and Caveats.
    Echaide M; Chocarro de Erauso L; Bocanegra A; Blanco E; Kochan G; Escors D
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing variant-adapted COVID-19 vaccines to improve protection against Omicron and other recent variants: a plain language summary.
    Pather S; Muik A; Rizzi R; Mensa F
    Expert Rev Vaccines; 2024 Dec; 23(1):463-466. PubMed ID: 38578120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.
    Rosenblum HG; Wallace M; Godfrey M; Roper LE; Hall E; Fleming-Dutra KE; Link-Gelles R; Pilishvili T; Williams J; Moulia DL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley MF; Meyer S; Oliver SE; Twentyman E
    MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(45):1436-1441. PubMed ID: 36355612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
    Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
    Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risks of Myocarditis and Pericarditis Following Vaccination with SARS-CoV-2 mRNA Vaccines in Japan: An Analysis of Spontaneous Reports of Suspected Adverse Events.
    Kobayashi H; Fukuda S; Matsukawa R; Asakura Y; Kanno Y; Hatta T; Saito Y; Shimizu Y; Kawarasaki S; Kihara M; Kinoshita N; Umeda H; Noda T; Imamura T; Nishioka Y; Yamaguchi T; Hayashi S; Iguchi T
    Ther Innov Regul Sci; 2023 Mar; 57(2):329-342. PubMed ID: 36310329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.
    Link-Gelles R; Ciesla AA; Fleming-Dutra KE; Smith ZR; Britton A; Wiegand RE; Miller JD; Accorsi EK; Schrag SJ; Verani JR; Shang N; Derado G; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(48):1526-1530. PubMed ID: 36454688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3-5 Years - Increasing Community Access to Testing Program, United States, July 2022-February 2023.
    Fleming-Dutra KE; Ciesla AA; Roper LE; Smith ZR; Miller JD; Accorsi EK; Verani JR; Shang N; Derado G; Wiegand RE; Pilishvili T; Britton A; Link-Gelles R
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(7):177-182. PubMed ID: 36795625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network.
    Neuhann JM; Stemler J; Carcas A; Frías-Iniesta J; Bethe U; Heringer S; Tischmann L; Zarrouk M; Cüppers A; König F; Posch M; Cornely OA
    Trials; 2022 Oct; 23(1):865. PubMed ID: 36209129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against symptomatic SARS-CoV-2 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original monovalent vaccines - A matched cohort study in France.
    Auvigne V; Tamandjou Tchuem CR; Schaeffer J; Vaux S; Parent Du Chatelet I
    Vaccine; 2023 Aug; 41(38):5490-5493. PubMed ID: 37541823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
    Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of two doses of BNT162b2 and mRNA-1273 vaccines for solid cancer patients on treatment with or without a previous SARS-CoV-2 infection.
    La Verde N; Riva A; Cona MS; Gabrieli A; Cattaneo M; Fasola C; Lipari G; De Stradis C; Favorito V; Lombardi Stocchetti B; Chizzoniti D; Covizzi A; Rulli E; Galli F; Ruggieri L; Gambaro A; Ferrario S; Dalu D; Tarkowski MS
    Int J Cancer; 2023 Feb; 152(4):661-671. PubMed ID: 36056571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute cardiac side effects after COVID-19 mRNA vaccination: a case series.
    Freise NF; Kivel M; Grebe O; Meyer C; Wafaisade B; Peiper M; Zeus T; Schmidt J; Neuwahl J; Jazmati D; Luedde T; Bölke E; Feldt T; Jensen BEO; Bode J; Keitel V; Haussmann J; Tamaskovics B; Budach W; Fischer JC; Knoefel WT; Schneider M; Gerber PA; Pedoto A; Häussinger D; van Griensven M; Rezazadeh A; Flaig Y; Kirchner J; Antoch G; Schelzig H; Matuschek C
    Eur J Med Res; 2022 Jun; 27(1):80. PubMed ID: 35655235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study.
    Monge S; Rojas-Benedicto A; Olmedo C; Mazagatos C; José Sierra M; Limia A; Martín-Merino E; Larrauri A; Hernán MA;
    Lancet Infect Dis; 2022 Sep; 22(9):1313-1320. PubMed ID: 35658998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
    Scheaffer SM; Lee D; Whitener B; Ying B; Wu K; Liang CY; Jani H; Martin P; Amato NJ; Avena LE; Berrueta DM; Schmidt SD; O'Dell S; Nasir A; Chuang GY; Stewart-Jones G; Koup RA; Doria-Rose NA; Carfi A; Elbashir SM; Thackray LB; Edwards DK; Diamond MS
    Nat Med; 2023 Jan; 29(1):247-257. PubMed ID: 36265510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components.
    Busà R; Sorrentino MC; Russelli G; Amico G; Miceli V; Miele M; Di Bella M; Timoneri F; Gallo A; Zito G; Di Carlo D; Conaldi PG; Bulati M
    Front Immunol; 2022; 13():856657. PubMed ID: 35401503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.